Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Jul 22;18(5 Suppl 4):20479.
doi: 10.7448/IAS.18.5.20479. eCollection 2015.

8th IAS Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2015)

No authors listed

8th IAS Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2015)

No authors listed. J Int AIDS Soc. .
No abstract available

PubMed Disclaimer

Figures

Abstract MOAA0101–Figure 1
Abstract MOAA0101–Figure 1
MVOA for detection of residual virus.
Abstract MOAA0103–Figure 1
Abstract MOAA0103–Figure 1
Individual correlations matrix.
Abstract MOAB0103–Figure 1
Abstract MOAB0103–Figure 1
Survival to one year by CD8+ T-cell activation.
Abstract MOAB0201–Figure 1
Abstract MOAB0201–Figure 1
Time to incident TB by IPT and HAART exposure.
Abstract MOAB0203–Figure 1
Abstract MOAB0203–Figure 1
TB-related death among HIV-positive patients according to the number of active drugs used as part of empiric TB therapy.
Abstract MOAB0204–Figure 1
Abstract MOAB0204–Figure 1
Comparison of TB treatment outcomes according to HIV status in 14 African Countries 2012 cohort.
Abstract MOAB0205LB–Figure 1
Abstract MOAB0205LB–Figure 1
KM graph for 5274
Abstract MOAC0103–Figure 1
Abstract MOAC0103–Figure 1
Treatment cost for FSW population.
Abstract MOAC0201–Figure 1
Abstract MOAC0201–Figure 1
ART outcomes for Option B+ patients.
Abstract MOAC0204–Figure 1
Abstract MOAC0204–Figure 1
Intrapartum transmission posterior probabilities.
Abstract MOAC0205LB–Figure 1
Abstract MOAC0205LB–Figure 1
Facility-level variation of average cost per service in two stages of the PMTCT cascade vs. scale.
Abstract MOAC0304LB–Figure 1
Abstract MOAC0304LB–Figure 1
Maximum likelihood phylogenetic tree of (a) HIV-1 pol sequences and (b) HCV NS 5b sequences.
Abstract MOAD0101–Figure 1
Abstract MOAD0101–Figure 1
WHO ARV Guidelines Adoption by region.
Abstract MOAD0103–Figure 1
Abstract MOAD0103–Figure 1
Major outcomes of early HAART programs at CCASAnet.
Abstract MOAD0105LB–Figure 1
Abstract MOAD0105LB–Figure 1
Number of patients receiving care within an Adherence Club and the proportion of all ART patients in the Cape Metro health district receiving care within an Adherence Club, January 2011–December 2014.
Abstract TUAA0203–Figure 1
Abstract TUAA0203–Figure 1
Eradication of HIV-1 DNA in latently infected cells. A. Treatment of latently infected T-lymphocytes with PMA and TSA activates viral gene expression and expression of GFP reporter in more than 93% of the cells. The presence of gRNAs (LTR A/B) and Cas9 dramatically prevented viral replication. B. Examination of DNA by PCR and direct sequencing verifies removal of integrated proviral DNA from chromosome 16.
Abstract TUAB0106LB–Figure 1
Abstract TUAB0106LB–Figure 1
Median change in HIV-1 RNA (log10 c/mL) over time.
Abstract TUAC0202–Figure 1
Abstract TUAC0202–Figure 1
Adherence, Risk Behavior and STI incidence Over Time in the Demo Project.
Abstract TUAC0204LB–Figure 1
Abstract TUAC0204LB–Figure 1
Tenofovir diphosphate levels (fmol/punch) and PrEP dosing estimates as measured by dried blood spot assay.
Abstract TUAC0302–Figure 1
Abstract TUAC0302–Figure 1
Proportion of HIV repeat testers.
Abstract TUAC0303–Figure 1
Abstract TUAC0303–Figure 1
Cumulative risk of acquiring HIV among MSM.
Abstract TUAC0401–Figure 1
Abstract TUAC0401–Figure 1
(a) Population size estimation using four independent methods, Maputio City. (b) Population size estimation using four independent methods, Nampula.
Abstract TUAC0404–Figure 1
Abstract TUAC0404–Figure 1
Retention on ART and viral suppression among PWID enrolled in the study disaggregated by CD4 at ART initiation.
Abstract TUAD0101–Figure 1
Abstract TUAD0101–Figure 1
HIV mortality along the care cascade.
Abstract TUAD0102–Figure 1
Abstract TUAD0102–Figure 1
Area under ROC curve with 95% CI (private programme).
Abstract TUAD0105LB–Figure 1
Abstract TUAD0105LB–Figure 1
Flowchart of programme implementation.
Abstract TUAD0202–Figure 1
Abstract TUAD0202–Figure 1
Participants tree.
Abstract TUAD0203–Figure 1
Abstract TUAD0203–Figure 1
PMTCT critical path.
Abstract TUAD0205–Figure 1
Abstract TUAD0205–Figure 1
Proportion of patients on ART Option B+ retained six months after treatment.
Abstract WEAB0101–Figure 1
Abstract WEAB0101–Figure 1
Total HIV-1 DNA (a) and integrated HIV-1 DNA (b) levels in four patient cohorts. Data is shown as log10 copies/million (c/M) PBMC and significant p-values are indicated by *. Differences between the cohorts were determined by Wilcoxon Signed Rank test.
Abstract WEAB0102–Figure 1
Abstract WEAB0102–Figure 1
Plasma viral load by 2G EIA reactivity.
Abstract WEAC0103–Figure 1
Abstract WEAC0103–Figure 1
Abstract WEAC0106LB–Figure 1
Abstract WEAC0106LB–Figure 1
Engagement of South African FSW in the HIV care cascade.
Abstract WEAD0101–Figure 1
Abstract WEAD0101–Figure 1
Kaplan-Meier plots over the first 18-months in a Community-based Adherance Club: (a) LTFU by gender, (b) LFTU by age, (c) Viral rebound by gender, (d) Viral rebound by age.
Abstract WEAD0104–Figure 1
Abstract WEAD0104–Figure 1
Figure in HIV care continuum outcomes in CCASAnet.
Abstract WEAD0105LB–Figure 1
Abstract WEAD0105LB–Figure 1
Viral suppression over time by ART initiation strategy.
Abstract WEAD0201–Figure 1
Abstract WEAD0201–Figure 1
Active referral increases paediatric HIV testing.
Abstract WEAD0203–Figure 1
Abstract WEAD0203–Figure 1
Children 0–14 years newly initiated on Antiretroviral therapy (July 2013 to June 2014).
Abstract WEAD0302–Figure 1
Abstract WEAD0302–Figure 1
(a) Optimized spending to minimize HIV incidence and AIDS-related deaths by 2020 in Armenia, (b) Sensitivity analysis of cost-coverage for seasonal migrant HIV testing and counselling program in Armenia.
Abstract WEAD0304–Figure 1
Abstract WEAD0304–Figure 1
Expected number of patients on first- and second-line ART in four selected, unnamed, sub-Saharan African countries. We assumed universal routine viral load monitoring, stable scale-up of ART initiation, and included treatment interruptions and delay in switching. Curves show the model projections and the points the observed numbers. Black/grey curves and points show the total number of patients, blue curves/points the patients on first-line ART and red/pink curves/points the patients on second-line ART.
Abstract WEAD0306LB–Figure 1
Abstract WEAD0306LB–Figure 1
Host Country Government Agency Allocations.
Abstract MOPDA0105–Figure 1
Abstract MOPDA0105–Figure 1
ML Tree.
Abstract MOPDC0103–Figure 1
Abstract MOPDC0103–Figure 1
Distribution of self-reported HIV tests by arm.
Abstract MOPDC0106–Figure 1
Abstract MOPDC0106–Figure 1
Uptake of PN services at 22 B + sites.
Abstract MOPDD0104–Figure 1
Abstract MOPDD0104–Figure 1
Lowess smooth of the percentage of female methadone clients.
Abstract TUPDC0101–Figure 1
Abstract TUPDC0101–Figure 1
Phylogenetic tree of subtype A sequences from PWIDs with evidence for cross-group transmissions plus sequences from the Greek epidemic sampled during 1999–2013 and a randomly selected global sample.
Abstract TUPDD0101–Figure 1
Abstract TUPDD0101–Figure 1
Testing under various stigma scenarios.
Abstract WEPDA0102–Figure 1
Abstract WEPDA0102–Figure 1
(a) Graphical presentations of patient longitudinal pre-ART data and regression lines obtained from a variable intercept linear mixed effects model showing longitudinal VL differences in infected B*58:02+vaccinees (blue, n=7) and placebo-recipients (red, n=7); ANOVA. (b) Kaplan-Meier curves showing time to CD4<350 cells/µl in infected HLA-B*58:02+vaccinees (blue, n=7) and placebo-recipients (red, n=7); log rank test.
Abstract WEPDB0103–Figure 1
Abstract WEPDB0103–Figure 1
Adjusted 12-month log hazard ratios of observed and corrected LTFU from Cox's proportional hazards models by CD4 count at ART initiation.
Abstract WEPDB0104–Figure 1
Abstract WEPDB0104–Figure 1
Action taken for the sampled patients with viral failure stratified by referral to the treatment failure path-way.
Abstract WEPDC0103–Figure 1
Abstract WEPDC0103–Figure 1
Flow chart – assignment of HIV acquisition.
Abstract WEPDC0105–Figure 1
Abstract WEPDC0105–Figure 1
HIV prevalence in each of the 40 RCCS communities.
Abstract WEPDD0101–Figure 1
Abstract WEPDD0101–Figure 1
Decision-analysis model schematic. Abbreviations: SOC-Standard of care, UPP-Universal fluconazole primary prophylaxis, CRAG-LFA–cryptococal antigen lateral flow assay, CM-cryptococcal meningitis, WTP-WHO pre-emptive therapy. Decision-analytic model schematic. We modeled progression or relapse of CM over a 5 year time-horizon for a cohort of PLWH with CD4 < 100. In all model arms symptomatic patients at baseline receive evaluation for CM assumed to include a lumbar puncture (LP), and treatment if diagnosed with CM. We assumed ART initiation in all arms. The model explores three interventions for prevention of cryptococcal morbidity for those without a baseline diagnosis of CM: 1) SOC, in which patients receive no CM screening or prophylaxis 2) UPP, in which all asymptomatic patients (and symptomatic patients without CM diagnosis * as noted in the model) receive primary prophylaxis with 200 mg of fluconazole. 3) CRAG-LFA, in which all patients receive serum CRAG-LFA screening. Individuals with positive CRAG were assumed to receive the WHO preemptive treatment for cryptococcemia with fluconazole 800 mg for two weeks, followed by fluconazole 400 mg for eight weeks. CRAG-negative individuals receive no further antifungal therapy.
Abstract WEPDD0102–Figure 1
Abstract WEPDD0102–Figure 1
Definitions of PITC models.
Abstract WEPDD0105–Figure 1
Abstract WEPDD0105–Figure 1
Trends of EID for HIV in southwestern Uganda: 2011–2014.
See this image and copyright information in PMC